Malignancy
Conditions
Interventions
Gold Standard:biopsy or surgical pathological diagnosis
Index test:68Ga/18F-PSMA
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with high suspicion of prostate cancer: (1) The serum PSA value has changed compared with the previous one (when PSA0.35ng/mL, or the annual change is >0.75ng/mL when PSA>4.0ng/mL); (2) First- and second-degree relatives with a history of prostate cancer; (3) For patients with nuclear magnetic resonance PI-RADS score >= 3 or prostate cancer confirmed by biopsy or surgical pathology, clinical laboratory test results (blood routine, biochemistry, serum PSA) within one month before PET/CT examination can be provided ; there are at least two other imaging examinations including CT, MRI, nuclear medicine, ultrasound and other imaging techniques; the examination can be completed independently. 2. For patients with breast cancer, kidney cancer, thyroid cancer, colorectal cancer and other malignant tumors who have been diagnosed, the clinical laboratory test results (blood routine and biochemistry) within one month before the PET/CT examination can be provided; there are at least two other imaging examinations including CT, MRI, nuclear medicine, ultrasound and other imaging techniques; the examination can be completed independently. 3. Patients can fully understand and voluntarily participate in this trial, and sign the informed consent.
Exclusion criteria
Exclusion criteria: There is a history of other malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Positive Predictive Value;Negative Predictive Value;Accuracy; | — |
Countries
China
Contacts
Public ContactFan Yan
Peking University First Hospital
Outcome results
None listed